<DOC>
	<DOCNO>NCT00221026</DOCNO>
	<brief_summary>study explore safety activity ECP treatment UVADEX induce clinical response ( i.e. , CDAI decrease great equal 100 baseline and/or CDAI &lt; 150 ) 12-week period moderately active Crohn 's disease ( CDAI great equal 220 &lt; 450 ) patient refractory intolerant immunosuppressant and/or anti-TNF agent . This study also assess response continue treatment 12-week Extension Period patient clinical response Week 12 Treatment Period elect participate Extension Period .</brief_summary>
	<brief_title>Safety Efficacy Extracorporeal Photoimmune Therapy With UVADEX Treatment Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Methoxsalen</mesh_term>
	<criteria>Signed date informed consent must obtain prior conduct study procedure . Patients must great equal 18 year age . Patients must body weight great equal 40 kg ( 88 lb ) . Patients must Crohn 's disease least 6 month duration ( colitis , ileitis , ileocolitis ) confirm radiography endoscopy . Patients must CDAI great equal 220 &lt; 450 . Patients must CRP concentration &gt; 10.0 mg/L ( 1.0 mg/dL ) evidence active inflammatory luminal Crohn 's disease demonstrate superficial and/or deep ulceration , pseudopolyps , and/or ulcerated stenosis colonoscopy within 8 week screen . Patients receive corticosteroid must prednisone equivalent dose less equal 25 mg/day oral ( PO ) budesonide dose less equal 9 mg/day . Patients receive follow concomitant Crohn 's disease medication must stable dose medication specify period time PRIOR TO confirmation eligibility ( time period may include screen ) : aminosalicylates , antibiotic , immunosuppressant ( i.e. , 6 MP , MTX , AZA ) least 4 week ; corticosteroid PO budesonide least 2 week ; antiTNF agent ( i.e. , infliximab adalimumab ) least 8 week . Patients fail treatment immunosuppressant and/or antiTNF agent . Patients fistulae permit , provide : patient predominantly luminal Crohn 's disease , fistulae associate abscess formation . Patients must platelet count great equal 50,000/microL ( 50.0 x 109/L ) . Female patient must : postmenopausal , surgically incapable bearing child , practice acceptable method birth control ( acceptable method include hormonal contraceptive , intrauterine device , spermicide barrier ) . Abstinence partner/spouse sterility may also qualify Investigator 's discretion . If female patient childbearing potential , must negative urine pregnancy test screening . Male patient must also commit use adequate contraceptive precaution ( condom ) . All patient ( male females childbearing potential ) must commit use adequate contraceptive precaution throughout participation study least 3 month follow last ECP treatment Patients must able willing comply study procedure . Patients concomitantly use biologic agent antiTNF agent ; cyclosporine ( CSA ) , tacrolimus ( FK506 ) , mycophenolate mofetil ( MMF ) , investigational Crohn 's disease therapy . Patients , opinion Investigator , may able remain stable dose concomitant Crohn 's disease medication 12week Treatment Period . Patients currently symptomatic untreated diarrhea , due condition inflammatory Crohn 's disease ( e.g. , bacterial parasitic gastroenteritis , bile salt diarrhea , bacterial overgrowth ) . Patients symptomatic intestinal stricture . Patients stomas . Patients local manifestation Crohn 's disease abscesses , disease manifestation surgery might indicate , might preclude utilization CDAI ass response therapy ( `` short gut '' syndrome ) . Patients unable tolerate extracorporeal volume shift associate ECP treatment due presence follow condition : uncompensated congestive heart failure , pulmonary edema , severe chronic obstructive pulmonary disease , severe asthma , renal failure , hepatic failure . Patients receive total parenteral nutrition , sole source nutrition , within 3 week screen . Female patient whose hemoglobin ( Hgb ) &lt; 8.5 g/dL male patient whose Hgb &lt; 10.0 g/dL screening . Patients poor tolerability venipuncture lack adequate venous access require treatment blood sampling . Patients know hypersensitivity allergy psoralen ( methoxsalen ) . Patients know hypersensitivity allergy heparin citrate product . Female patient pregnant and/or lactating . Patients enrol investigational study treatment Crohn 's disease within 4 week enrollment non biologic therapy within 8 week enrollment biologic therapy . Patients follow : coexist melanoma , squamous cell skin carcinoma , aphakia , photosensitive disease ( e.g. , porphyria , systemic lupus erythematosus , albinism ) , white blood cell count &gt; 25,000 mm3 , previous splenectomy , clinically significant coagulation disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>